TY - JOUR A1 - Parasramani, Shrichand A1 - Shirolikar, Manasi T1 - IL-23 blockers in dermatology Y1 - 2021/7/1 JF - Indian Journal of Drugs in Dermatology JO - Indian J Drugs Dermatol SP - 51 EP - 59 VL - 7 IS - 2 UR - https://www.ijdd.in/article.asp?issn=2455-3972;year=2021;volume=7;issue=2;spage=51;epage=59;aulast=Parasramani DO - 10.4103/ijdd.ijdd_24_21 N2 - Interleukin-23 (IL-23) is the key regulatory cytokine in psoriasis, which stimulates differentiation, proliferation, and survival of T-helper 17 (Th17) cells. Specific targeting of IL-23–IL-17 inflammatory pathway has become an effective therapeutic approach to treat psoriasis. Clinical studies have shown that antibodies directed against the p19 subunit of IL-23 show equal or superior response as compared to when both IL-12 and IL-23 are inhibited. Side effects of IL-12 inhibition are avoided. Tildrakizumab, guselkumab, and risankizumab are antibodies that target the p19 subunit of IL-23. These newer IL-23 blockers give high PASI response and are easy to administer once in 8–12 weeks. A comparison of these three drugs from different trials is carried out in this review with the help of bar charts. There are no head-to-head comparative trials of these monoclonal antibodies. ER -